John Maraganore
CIK 1180432 · Chief Executive Officer · last filed 2026-10-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALNY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RAPP | Director | 8,239 | $27.41 | $225.8K | $248.9K | 3 | 2026-10-22 |
| CTY | Director | 1,789,199 | — | — | $0 | 1 | 2026-10-19 |
| TAK | Director | 13,800 | $20.30 | $280.1K | $0 | 1 | 2026-07-06 |
| KYMR | Director | — | $118.02 | — | $0 | 5 | 2026-06-25 |
| BEAM | Director | — | $24.77 | — | $0 | 6 | 2026-06-05 |
| COAG | Director | 35,948 | $37.14 | $1.34M | $0 | 1 | 2026-05-04 |
| PROK | Director | — | $1.46 | — | $0 | 1 | 2023-07-03 |
| AGIO | Director | 30,028 | $37.23 | $1.12M | -$1.80M | 18 | 2022-06-23 |
| ALNY | Chief Executive Officer | 231,115 | $225.05 | $52.01M | -$114.58M | 77 | 2021-12-23 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 1,236 | $4.97 | $6.1K | -$4.68M | 9 | 2017-09-18 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | 51,254 | $8.16 | $418.2K | $0 | 1 | 2012-10-11 |
Recent Filings · Page 8 of 13
124 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-12-22 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2016-12-14 | ALNY | Mixed | +7,441 | -$281.7K | EDGAR |
| 2016-10-14 | ALNY | Exer (M) | +7,540 | $100.0K | EDGAR |
| 2016-07-21 | ALNY | Mixed | — | -$1.26M | EDGAR |
| 2016-06-23 | AGIO | Grant (A) | — | $0 | EDGAR |
| 2016-06-03 | bluebird bio, Inc. (BLUE) Delisted | Grant (A) | +1,000 | $0 | EDGAR |
| 2016-04-21 | ALNY | Mixed | — | -$1.35M | EDGAR |
| 2016-02-03 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2016-01-21 | ALNY | Mixed | — | -$1.48M | EDGAR |
| 2015-12-22 | ALNY | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.